CHEM-X-INFINITY partnered with I-Stem Institute to identify new treatments for monogenic diseases. Chem-X-Infinity will supply compound libraries, library focusing and early hit-optimization.

CHEM-X-INFINITY will attend the 21st International Symposium of Medicinal Chemistry on September 5-9th, 2009, in Brussels, Belgium.

CHEM-X-INFINITY is pleased to announce a new library focused on kinases, DNA processing enzymes and GPCRs. The original azaindole scaffold could be useful for the identification of new potent series. The library was co-designed with Provence Technologies which is a company specialized in the synthesis of azaindoles.

CHEM-X-INFINITY is pleased to announce a new library focused on proteases. Two versatile linkers have been used to synthesize compounds able to interact with serine and cysteine residues of proteins. The compounds could also have applications in GPCRs and antibiotics.

CHEM-X-INFINITY released a new focused library centered on the linker dialkylaminoamide. This versatile linker can be found in various active molecules targeting enzymes, ion channels and GPCRs. A selection of potent peptidomimetic structures is also presented.

CHEM-X-INFINITY is pleased to announce that it has received the accreditation for the French R&D tax credit for years 2009 to 2012. The system allows French companies to have a tax credit for R&D services outsourced in approved companies.

CHEM-X-INFINITY released a new focused library centered on the pyrazole propionamide scaffold. Many strategies for the synthesis of pyrazoles are described in the literature. We used an original cyclisation to obtain pyrazole propionamides that could have applications in the GPCR field and for the discovery of new NSAIDs.

CHEM-X-INFINITY is pleased to present a new diverse library centered around the quinoline carboxamide scaffold. This small and versatile heterocycle offers many interaction possibilities with diverse receptors as peptide and amine GPCRs or ion channels. The library is a good collection for first intention screenings.

CHEM-X-INFINITY attended the 5th Drug Design and Lead Discovery Summit on October 14-16th, 2009, in San Diego, CA. The event covered new and common challenges faced during the research phase of the drug discovery process, as well as exciting and pertinent success stories. The conference had a focus on ligand-based drug design strategies that highlight the alternates, value, applicability, efficacy and effectiveness of pharmacophore-based strategies for lead finding and optimization.

CHEM-X-INFINITY released a new focused library centered around the dihydroquinazolinone scaffold. Using a well-known two steps connecting chemistry and diverse sets of amines and aldehydes, the compounds could be useful for the research of new diuretics, analgesics, antibiotics and anti-tumoral compounds.